Clinical trials: Checkpoint Inhibitor, open to volunteers
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma
- Trial name
- NCT05741164
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Advanced Or Metastatic Merkel Cell Carcinoma
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with…
- Trial name
- NCT06947928
- Testing
- IFx-Hu2.0, Pembrolizumab
- Where
- 18 sites in United States
- Volunteers
- 118 people
- Sponsor
- TuHURA Biosciences, Inc.
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
This is an open-label, randomized, multi-cohort, multi-center, phase Ib/II study to evaluate the safety and efficacy of Adebrelimab plus Irinotecan Liposome (II) with or without Famitinib in patients with extensive-stage small…
- Trial name
- NCT06332950
- Testing
- Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Baohui Han
Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
- Trial name
- NCT07186621
- Testing
- Sintilimab, radiotherapy, TACE
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Any Advanced Solid Tumors
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the…
- Trial name
- IRIS (NCT07836101)
- Testing
- Sarilumab, ICI Therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasopharyngeal Carcinoma
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication…
- Trial name
- NCT06239727
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2)
- Where
- 26 sites in China
- Volunteers
- 593 people
- Sponsor
- Sun Yat-sen University
Solid Tumor
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.
- Trial name
- NCT07843550
- Testing
- Larotrectinib, Pembrolizumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Recurrent or Metastatic Head and Neck Carcinoma
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a single-center, open-label phase 2 study evaluating sacituzumab tirumotecan in combination with an immune checkpoint inhibitor in patients with previously treated recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT07686588
- Testing
- Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor
- Volunteers
- 20 people
- Sponsor
- Biying Chen
HIPEC, Ovarian Serous Adenocarcinoma
Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study
Background: Advanced ovarian cancer is a highly dangerous disease, and many patients lose their lives due to limited treatment effectiveness.
- Trial name
- ICI-HIPET (NCT07068178)
- Testing
- ICI-HIPET
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jing Li
Sarcoma, Sarcoma,Soft Tissue
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced…
- Conditions
- Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone
- Trial name
- PRIMA (NCT06074692)
- Testing
- Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Ruijin Hospital
Acute Kidney Injury, Acute Interstitial Nephritis
Infliximab for Immune Checkpoint Inhibitor Associated AKI
This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone…
- Trial name
- NCT07683975
- Testing
- Infliximab, Prednisone, prednisone (oral)
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Massachusetts General Hospital
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Inflammatory Arthritis, Immune-related Adverse Event
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
This study will examine the effectiveness of administering adalimumab as a treatment for patients in the early stages of steroid-dependent immune checkpoint Inhibitor associated inflammatory arthritis (ir-IA).
- Trial name
- NCT06037811
- Testing
- Adalimumab, Prednisone
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Tom Appleton
Immune-mediated Hepatitis, Immune-related Adverse Event
Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
This phase II study evaluates whether early treatment with mycophenolate mofetil (MMF) plus prednisone improves liver inflammation caused by immune checkpoint inhibitors.
- Trial name
- NCT07663422
- Testing
- Mycophenolate Mofetil plus prednisone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Fox Chase Cancer Center
Lung Cancer, Myocarditis Due to Drug
Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
This study aims to investigate the clinical classification and outcome-related biomarkers of immune checkpoint inhibitor (ICI)-related myocarditis in patients with lung cancer.A total of 50 patients with ICI-related myocarditis…
- Trial name
- NCT06818149
- Testing
- Biomarker Analysis for Severity Assessment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Locally Advanced Nasopharyngeal Carcinoma
Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma
This is a multicenter, open-label, randomized phase II clinical trial designed to evaluate the optimal timing of toripalimab administration during neoadjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal…
- Trial name
- NCT07388836
- Testing
- Toripalimab
- Volunteers
- 198 people
- Sponsor
- Fujian Cancer Hospital
Immune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions
Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation
This is a prospective, single-center, open-label, randomized controlled clinical trial evaluating whether the addition of a nutritional therapy regimen (Spirulina-Bifidobacterium capsules, fish oil-grape seed-blueberry soft…
- Conditions
- Immune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07554885
- Testing
- Spirulina-Bifidobacterium capsule, Fish oil-grape seed-blueberry soft capsule, Ganoderma spore oil
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed).
- Trial name
- NCT04546399
- Testing
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection
- Where
- 227 sites in United States, Australia and 2 more
- Volunteers
- 461 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Carcinoma Cell
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
Effective later-line treatment options remain an unmet medical need for patients with advanced esophageal squamous cell carcinoma (ESCC) whose disease has progressed after prior immunotherapy, particularly given the widespread…
- Trial name
- NCT07688291
- Testing
- PD-1/IL-2α-bias bispecific antibody fusion protein
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing GoBroad Hospital